

Metabolic Evaluation of Non–Small Cell Lung Cancer Patient–Derived Xenograft Models Using ^{18}F -FDG PET: A Potential Tool for Early Therapy Response

Silvia Valtorta*^{1,2}, Massimo Moro*³, Giovanna Prisinzano^{1,4}, Giulia Bertolini³, Monica Tortoreto⁵, Isabella Raccagni^{2,4}, Ugo Pastorino⁶, Luca Roz³, Gabriella Sozzi^{†3}, and Rosa Maria Moresco^{†2,4}

¹National Researches Council (CNR), Molecular Bioimaging and Physiology Institute (IBFM), Segrate, Italy; ²Medicine and Surgery Department and Tecnomed Foundation, University of Milano–Bicocca, Monza, Italy; ³Tumor Genomics Unit, Experimental Oncology and Molecular Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; ⁵Molecular Pharmacology Unit, Experimental Oncology and Molecular Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; and ⁶Thoracic Surgery Unit, Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Lung cancer heterogeneity makes response to therapy extremely hard to predict. Patient-derived xenografts (PDXs) are a reliable preclinical model that closely recapitulates the main characteristics of the parental tumors and may represent a useful asset for testing new therapies. Here, using PET imaging, we investigated whether lung cancer PDXs reproduce the metabolic characteristics of the corresponding parental tumors. **Methods:** We performed longitudinal ^{18}F -FDG PET studies on 9 different PDX groups obtained by implanting primary-cancer fragments harvested from patients into mice. The SUV_{max} of each PDX was calculated and compared with the SUV_{max} of the corresponding parental tumor. **Results:** Tumor growth rate and uptake varied among the different PDXs and confirmed the preservation of individual characteristics. The intragroup reproducibility of PET measurements was good. Furthermore, PDXs from tumors with a higher metabolic rate displayed a rank order of uptake similar to that of the parental tumors. **Conclusion:** PDXs reproduced the glucose metabolism of the parental tumors and therefore represent a promising preclinical model for the early assessment of therapy efficacy.

Key Words: ^{18}F -FDG PET; lung cancer; patient-derived xenograft; stem cells

J Nucl Med 2017; 58:42–47

DOI: 10.2967/jnumed.116.176404

Lung cancer is a heterogeneous disease characterized by poor outcome and limited response to pharmacologic treatment. The expanding knowledge about genetics and molecular biology has led to reconsideration of the classic histologic classification (1), suggesting personalized target-based or chemotherapeutic strategies according to the different molecular subtypes of tumors (2,3). Despite some efficacy in selected groups of patients treated with

epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors (4–6), this target-based approach has only marginally increased the overall survival of patients. Treatment of lung cancer still represents a major challenge since the presence of multiple modified pathways and the occurrence of therapy-induced mutations greatly limits efficacy (7). Development of second-generation kinase inhibitors, multitargeted combination therapy, and novel immune system–stimulating drugs may represent a novel strategy to reduce treatment failure (8).

Among other determinants of chemoresistance, cancer stem cells (CSCs, defined as the subset of tumor cells endowed with greater tumor-forming potential) have been suggested as another key factor in the limited efficacy of therapy because of their intrinsic chemoresistance and ability to support tumor regrowth (9,10). Development of agents targeting critical steps in CSC-deregulated pathways (i.e., Wnt, Notch, and Hedgehog) holds promise as an innovative therapeutic approach (11). In this context, we have previously shown that in lung cancer, CD133+ cells endowed with stemlike properties are resistant to cisplatin treatment (10), and we recently identified CD133+/CXCR4+/EpCAM– cells as metastasis-initiating (12).

Considering the high heterogeneity of lung cancer, preclinical models that recapitulate the specific genetic and cellular characteristics of primary tumors represent a major need in the identification and development of anticancer drugs. Patient-derived xenografts (PDXs), obtained by direct implantation of tissue fragments into immunocompromised mice, are of particular interest because they retain the morphology, architecture, and molecular signatures of the parental tumor more closely than is possible for in vitro established cell lines (13–15). PDXs have been used to identify specific determinants of therapeutic response (16,17) and even to predict the response of individual tumors to treatment (18–20). We previously reported the generation of non–small cell lung cancer (NSCLC) PDXs that closely maintained the biologic characteristics of the parental tumors, including histology, immunophenotype, resistance to platinum-based therapy, and CD133+ CSC content (21), and we demonstrated the potential for using PDXs to investigate the dynamics of CSCs during pharmacologic treatment (22).

The potential of PDXs to reproduce the metabolic characteristics of the corresponding parental tumors has, however, not

Received Mar. 30, 2016; revision accepted Jun. 22, 2016.

For correspondence or reprints contact: Luca Roz, IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

E-mail: luca.roz@istitutotumori.mi.it

*Contributed equally to this work.

†Contributed equally to this work.

Published online Oct. 20, 2016.

COPYRIGHT © 2017 by the Society of Nuclear Medicine and Molecular Imaging.

TABLE 1
Parental Tumor Phenotype

Group	Subtype	Pathologic stage	TNM	Grade	Size (cm)	CD133+	SUV _{max}
LT128	ADC	IIIA	T2N2M0	G3	5.5	2%	22.0
LT187	SCC	IIIA	T3N2M0	G3	7.0	ND	16.4
LT66	ADC	IIIA	T1N2M0	G3	1.9	0.2%	15.8
LT59	LCC	IIIA	T1N2M0	G3	2.7	2%	12.3
LT111	ADC	IIB	T2N1M0	G3	5.0	15%	8.4
LT73	ADC	IIA	T2N1M0	G2	4.0	20%	8.4
LT138	ADC	IA	T1N0M0	G3	1.3	ND	5.6
LT215	ADC	IV	T2N0M1	G3	4.0	ND	4.5
LT120	ADC	IA	T1N0M0	G1	1.5	23%	0.7

ADC = adenocarcinoma; SCC = squamous cell carcinoma; LCC = large cell carcinoma; ND = not determined.

been investigated. This has important clinical implications because metabolic reprogramming is now recognized as a hallmark of cancer cells (23) and several preclinical and clinical studies have indicated that in vivo imaging of the Warburg effect with ¹⁸F-FDG serves as a noninvasive surrogate marker for early prediction of prognosis and for assessment of the response to pharmacologic treatment, including targeted therapies (24–26). Even for lung cancers detected by screening, stratification of patients on the basis of ¹⁸F-FDG uptake (quantified as SUV_{max}) has been shown to have prognostic value (27). In particular, we observed that an SUV_{max} of less than 2.5 defined a homogeneous group of small, stage Ia, tumors (median diameter, 11 mm; range, 5–16 mm) with a 100% 5-y survival. In contrast, an SUV_{max} of more than 8 defined a group of mostly advanced cancers (only 8% stage Ia) whose 20% survival indicated a highly metastatic biologic profile (27).

Specific mutations can also influence metabolic activity; in particular, mutation or overexpression in tyrosine kinase receptors, PI3K/Akt/mTOR, RAS/RAF/MAPK, or liver kinase B1 (LKB1)

results in increased activation of downstream signaling pathways that participate in reprogramming of tumor cell metabolism and influence uptake (28,29).

To investigate whether NSCLC PDXs maintain the metabolic characteristics of the parental tumors, we selected from our previously established NSCLC PDXs those deriving from patients who underwent a presurgery ¹⁸F-FDG PET measurement, and we compared the SUV_{max} of the PDX with that of the corresponding parental tumor. Furthermore, we assessed whether other features of PDXs, such as tumor engraftment, growth rate, and CSC content, are associated with SUV_{max}. PDXs originating from tumors with an SUV_{max} of more than 8 correlated well with the SUV_{max} of the parental tumors, underscoring the potential for using ¹⁸F-FDG PET in PDXs during preclinical development of novel therapeutic approaches.

MATERIALS AND METHODS

PDX Establishment

The Internal Review and the Ethics Boards of Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) approved this study, and

TABLE 2
PDX Phenotype

Group	Latency* (d)	SGR*	CD133+	CD133+ CXCR4+	EpCAM [†]	KRAS (G12C)	LKB1	SUV _{max} *
LT128	34.3 ± 5.4	0.06 ± 0.02	1.5%	4.8%		mut	(c.920 + 2T > A)	2.84 ± 0.41
LT187	29.3 ± 3.1	0.05 ± 0.01	0.2%	6%		wt	wt	0.97 ± 0.44
LT66	11.6 ± 1.3	0.13 ± 0.02	0.5%	ND		mut	c.298C > T	0.81 ± 0.15
LT59	38.8 ± 3.1	0.07 ± 0.02	85%	0.8%		wt	wt	0.74 ± 0.19
LT111	17.8 ± 2.0	0.09 ± 0.01	15%	2%		wt	wt	0.73 ± 0.14
LT73	18.3 ± 2.6	0.08 ± 0.03	3%	0.5%		wt	c.859A > T	0.37 ± 0.08
LT138	61.7 ± 8.1	0.07 ± 0.00	85%	0.3%		ND	c.354delC	1.16 ± 0.16
LT215	25.8 ± 7.4	0.10 ± 0.01	0.2%	4%		ND	wt	1.30 ± 0.33
LT120	25.0 ± 6.2	0.13 ± 0.02	30%	95%		ND	ND	1.34 ± 0.15

*Mean ± SD (*n* = 3/6 animals per group).

[†]Within CD133+ cells.

SGR = specific growth rate; mut = mutation; wt = wild type; ND = not determined.




FIGURE 1. ^{18}F -FDG PET scan of representative mouse for each group, intravenously injected with 4.2 ± 0.3 MBq after overnight fasting. Arrows indicate tumors.

all subjects gave written informed consent (10). Tumor specimens from patients who underwent presurgical ^{18}F -FDG PET were selected. Patient ^{18}F -FDG SUV_{max} was masked from the researchers who participated in the preclinical PET study.

Female CD-1 nude or SCID mice (7–10 wk old) were purchased from Charles River Laboratories. The animals were kept under specific pathogen-free conditions and were handled and maintained according to the ethical regulations of the Institutional Animal Care and Use Committee of Fondazione IRCCS Istituto Nazionale dei Tumori and IRCCS Ospedale San Raffaele. The PDX models were established as previously described (21).

PET Analysis and Quantification

Groups of animals (5 or 6 per group) underwent ^{18}F -FDG PET weekly for a month, starting when the tumor size was consistent with the spatial resolution of the preclinical PET scanner (4–5 mm). At the first PET scan, tumor volume varied from 50 to 139 mm^3 . Weekly, the animals were monitored for weight loss and tumor size, which was measured with a caliper (volume = $(a \times b^2)/2$, with a being the long side and b the short side). PET analysis and quantification were as previously described (26).

Tumor growth rate was calculated during the exponential growth phase and was quantified using specific growth rate ($1/d$) as $\ln(V_2/V_1)/(t_2 - t_1)$, with V being tumor volume and t the time of measurement (30), and then was correlated with uptake expressed both as SUV_{max} and as tumor-to-background ratio. Specific growth rate was evaluated during different time frames to include only the linear part of the growth curve.

Measurement of CD133+ and CD133+/CXCR4+/EpCAM- Cells on PDXs

CD133+ CSCs and the disseminating CD133+/CXCR4+/EpCAM- subset were detected using previously described procedures (10,12).

Statistical Analysis

Results are expressed as mean \pm SD or SEM where indicated. Correlation (R^2) was determined using the parametric Pearson test (2-tailed, 95% confidence interval) with Prism software (Graph Pad) and was considered statistically significant when the P value was less than 0.05. Linear regression was also calculated using Prism.

RESULTS

Establishment of PDXs from Varying Parental Tumors

Nine different PDX groups were evaluated during the study (Table 1): 7 derived from adenocarcinomas, 1 from a squamous cell carcinoma, and 1 from a large cell carcinoma. The groups had different clinical stages (1 stage IV, 4 stage IIIA, 2 stage IIB, and 2 stage IA), different degrees of lymph node involvement (4 N2, 2 N1, and 3 N0), and different degrees of CD133+ CSC content (4 had $>15\%$ CD133+ cells, 2 had 1%–15%, and 3 had $<1\%$). Different driver mutations were also observed (2 groups showed mutations in KRAS, 4 in LKB1, and 1 in ERBB2). The groups also had different latency times (time from implantation to presence of palpable tumor; range, 11.6–61.7 d) and specific growth rates (range, 0.05 to 0.13) (Table 2). All these data confirm the unique nature of individual PDXs. In particular, 6 groups were from parental tumors with an SUV_{max} of more than 8, but the other 3 were from parental tumors with an SUV_{max} of less than 6: two greater than 2.5 and one less than 2.5.

Reproducibility, Intragroup Homogeneity, and Intergroup Heterogeneity of PDX SUV_{max}

Under PET examination, the PDXs showed variable uptake (Table 2), as reflects the heterogeneity observed in the parental tumors. In some PDXs, uptake was high and the tumors were easily detectable (e.g., LT128, LT187, LT66, and LT120); in others, uptake was low and the tumors poorly detectable (e.g., LT73) (Fig. 1). During the observation time, mouse weight remained stable and no other clinical or behavioral changes were observed with the exception of LT138, which induced cachexia at later time points (Supplemental Fig. 1; supplemental materials are available at <http://jnm.snmjournals.org>). In some PDXs (LT66, LT111, LT120, LT128, and LT138), necrosis was visible on the PET images when the tumors grew larger than 300 mm^3 , but when we evaluated for correlations at volumes of 150 mm^3 , ^{18}F -FDG was homogeneously distributed within the tumors.

Among the group of low-metabolism PDXs, LT215 (parental tumor SUV_{max} , 4.5) displayed an abrupt and sudden increase in size and uptake between the second and the third scans (from 66.1 ± 35 to 137 ± 57 mm^3 and from an SUV_{max} of 0.62 ± 0.1 to 1.3 ± 0.3) as shown in Figure 1. Interestingly, this tumor had no nodal involvement at diagnosis but was associated with a synchronous brain metastasis.




FIGURE 2. (A) SUV_{max} distribution in LT66 PDX with similar tumor dimensions (about 800 mm³) after 18 and 34 *in vivo* passages. (B) Measurement of uptake in multiple exponentially growing PDXs.

To evaluate the influence of serial passages in the murine host on tumor metabolism, we evaluated uptake in the same PDX (LT66) at 2 different serial passages (p18 and p34). LT66 displayed a similar rate of growth at both p18 and p34, as well as a similar SUV_{max} (p18: SUV_{max}, 1.27 ± 0.15, and tumor volume, 874.40 ± 273.18 mm³; p34: SUV_{max}, 1.28 ± 0.14, and tumor volume, 785.42 ± 303.21 mm³) (Fig. 2A). We observed a general but not continuous increase in necrosis after p10, with comparable amounts of necrotic areas, slightly higher than in parental tumor but similar to each other.

Intramodel metabolic variability was generally low except for LT128 and LT187 (Fig. 2B; Supplemental Fig. 2), which displayed a bimodal distribution. In both cases, half the PDXs analyzed showed a higher uptake, which could reflect differences in the cell populations of the parental tumors.

Correlation of Uptake with Clinicopathologic Characteristics of Tumors

Association analysis showed that neither tumor growth rate nor CD133+ CSC content was related to SUV_{max} or change in SUV_{max} (Figs. 3A and 3B). However, when outliers (>6%) were removed, a slight positive correlation in PDXs was observed between SUV_{max} and the relative disseminating-CSC content (CD133+/CXCR4+/EpCAM-) within the CSC pool ($R^2 = 0.79$, $P = 0.06$).

Finally, when we considered the group of PDXs as a whole, we found no statistical correlation between uptake in the PDXs and uptake in the corresponding parental tumors (Fig. 4A). In detail, the 3 PDXs from parental tumors with an SUV_{max} of less than 8

and absence of nodal involvement failed to maintain the rank order of SUV_{max} of the corresponding parental tumors (Table 3). In contrast, the PDXs from the remaining parental tumors (with nodal involvement and an SUV_{max} of more than 8) tended to have glucose metabolism similar to that of the parental tumors ($R^2 = 0.72$, $P < 0.05$) (Fig. 4B).

DISCUSSION

Being able to evaluate the efficacy of treatment early is of fundamental importance in the clinical management of patients.

¹⁸F-FDG PET represents an interesting tool for the early assessment of drug efficacy (25,31) and can be used to image PDXs, which reproduce the characteristics of the parental tumor regarding immunohistochemical markers, genetic alterations, and maintenance of cellular heterogeneity (20,21). Here, using PET imaging, we evaluated glucose metabolism in PDXs from NSCLC patients who underwent ¹⁸F-FDG PET. The tumors of the patients had different clinicopathologic characteristics, and the growth rates and glycolytic phenotypes of the PDXs were highly variable.

¹⁸F-FDG uptake can be affected by modifications and rearrangements in some genes, such as ALK, EGFR, KRAS, ERBB2, and LKB1. Recently, Choi et al. observed that lung cancer patients with ALK rearrangement showed higher glucose metabolism than patients with EGFR mutations or wild-type patients for both genes (32). In other tumor types, mutations in KRAS/BRAF or in LKB1 are generally related to a high-glycolysis phenotype (29,33,34).

Among our highly glycolytic PDXs, LT128 and LT66 displayed mutations both in the KRAS gene (c.34G > T) and in the LKB1 gene (c.920 + 2T > A and c.298C > T, respectively), which could partially explain the high uptake. Also, LT73 and LT138 showed mutations in the LKB1 gene (c.859A > T and c.354delC, respectively) but not in the KRAS gene and displayed a different SUV_{max}. The correlation between specific gene alterations and glycolytic phenotype should therefore be investigated in greater detail, potentially taking into account interactions among multiple mutations.




FIGURE 3. (A) Tumor growth rate in different PDX groups ($n = 4-6$ per each group). Error bars express SEM. (B) Lack of correlation between tumor growth rate and uptake in PDXs. Error bars express SD.




FIGURE 4. (A) Lack of correlation between parental tumors and corresponding PDXs. (B) Significant correlation after exclusion of PDXs from parental tumors with $SUV_{max} < 8$ (red points). Even when highest SUV_{max} point was eliminated, correlation remained good ($R^2 = 0.62$). Uptake is expressed as SUV_{max} .

In comparing uptake in PDXs with that in the corresponding parental tumors, we observed that PDXs from tumors with an SUV_{max} of more than 8 showed the same uptake behavior as the parental tumors. This subgroup represents higher-glycolysis tumors, which have higher metastatic potential and the worst prognosis among screening-detected lung cancers (Fig. 4B) (27). For patients with such tumors, identification and development of pharmacologic treatment remains an unmet clinical need. In our previous study, the glycolytic phenotype of tumor cells influenced the response to VEGF-targeted treatment and the acquisition of resistance, which could be monitored by PET imaging (26). In this context, metabolic alterations could be an interesting target for novel therapeutic approaches (26,34).

SUV_{max} did not correlate between the 3 PDXs from tumors with an SUV_{max} of less than 8 and their corresponding parental tumors. Two of these were from low-stage tumors (IA), one of which was carrying an LKB1 mutation (c.354delC). The third (LT215) was from a small primary tumor (T2) with an SUV_{max} of 4.5, no evidence of lymph node involvement, but synchronous brain metastasis. This PDX displayed a sudden and abrupt increase in size and uptake, possibly reflecting the aggressiveness of the parental tumor. We hypothesized that when the PDX was smaller, during the early phase of engraftment, it recapitulated the glucose metabolism of the parental tumor but that a subpopulation of cells with a more aggressive phenotype already present in the parental tumor possibly

TABLE 3
Comparison of SUV_{max} Between Parental Tumors and PDXs

Group	Parental tumor	PDX
LT128	22	2.84
LT187	16.4	0.97
LT66	15.8	0.81
LT59	12.3	0.74
LT111	8.4	0.73
LT73	8.4	0.37
LT138	5.6	1.16
LT215	4.5	1.30
LT120	0.7	1.34

then took over (Fig. 1). As previously stated, the SUV_{max} of PDXs from poorly glycolytic parental tumors lacking nodal involvement failed to maintain the glycolytic phenotype of the parental tumors (Fig. 4A; Table 3). Considering that engraftment is generally more difficult for such PDXs, we assume that selection of PDXs with more resistant cells and higher glucose metabolism might have supported the engraftment.

Concerning model reproducibility, we observed that uptake, measured during the exponential phase after engraftment and at comparable tumor size, was homogeneous within the same PDX group with the exception of LT128 and LT187, which showed similar although

bimodal metabolic behavior that could reflect differences in the cell populations of the parental tumors. In our platform of 38 lung cancer PDXs, we have consistently observed that PDXs maintain the parental tumor characteristics (histologic type, main histologic patterns, marker expression, genetic profile, stromal content, degree of necrosis, and stem cell content) for several passages in the animal (>p10) (21). In the single case analyzed in this study, we observed the same metabolic phenotype regardless of the number of passages. PDXs are generated by subcutaneous implantation of a small fragment of parental tumor into a mouse, after which the engrafted tumor is reduced into fragments and transferred to other animals. Although—in view of this possible source of variability—a certain intralésional variability could sometimes be observed, the intra-group reproducibility of the measurements was remarkable.

As previously indicated, PDXs recapitulated the biologic characteristics of the corresponding parental tumors, including CD133+ CSC content and resistance to platinum therapy (10,21). Stem cell-like properties are closely related to chemoresistance phenotype, but because of the low number of CSCs within parental tumors, it is difficult to use CSC markers in clinical practice and it is challenging to visualize them with molecular imaging (35). Like Gaeddicke et al., we found no correlation between CD133 expression and glucose metabolism as measured by SUV_{max} (36). In fact, in that study CD133+ cells could be imaged only by using a specific ^{64}Cu -conjugated antibody-based tracer. However, we observed a tendency for tumors with a higher SUV_{max} to have a greater relative disseminating-CSC content (CD133/CXCR4/EpCAM-), which we recently identified as being modulated by microenvironmental cues and related to a bad clinical outcome in NSCLC patients (12). This could indicate a propensity for tumors with high glycolytic activity to induce selective enrichment of CSCs with disseminating ability, possibly providing a link between high SUV_{max} and worst prognosis.

Strategies to improve imaging of CSCs will be needed to evaluate the potential clinical relevance of CSC tracking. In a recent study on a mouse model of colon carcinoma (colon-26), Yoshii et al. observed high uptake of ^{64}Cu -diacetyl-bis(N^4 -methylthiosemicarbazone) within regions with a high density of CD133+ cells whereas regions with a high uptake of ^{18}F -FDG had the lowest presence of CD133+ (37). Moreover, in mice implanted with Lewis lung carcinoma cell line LLC1, Oh et al. found an accumulation of ^{64}Cu -diacetyl-bis(N^4 -methylthiosemicarbazone) in tumor regions comprising quiescent but clonogenic cells with low

glucose metabolism (38). Altogether, these studies suggest that specific tracers identifying a CSC subset with relative quiescence and low metabolic activity might be more useful than ^{18}F -FDG and might be implemented in association with PET to gain more information on tumor response during treatment.

CONCLUSION

Lung PDXs from parental tumors with an SUV_{max} of more than 8 mirror not only the histologic characteristics and CSC content of the parental tumors but also their metabolic activity, suggesting greater usefulness in more aggressive tumors with higher metabolism. The combined use of PDXs and metabolic imaging could therefore represent a powerful preclinical tool for drug discovery and testing.

DISCLOSURE

This work was supported by AIRC (Associazione Italiana per la Ricerca sul Cancro; IG13403 to Luca Roz, IG14318 to Gabriella Sozzi, IG15928 to Ugo Pastorino, and 12162 ["Innovative Tools for Cancer Risk Assessment and Early Diagnosis," 5x1000]); the European Community Seventh Framework Program (FP7/2007-2013); grant HEALTH-F2-2010-258677 from Collaborative Project CURELUNG to Luca Roz; and grants RF-2010-2306232 and 2310201 from the Italian Ministry of Health to Gabriella Sozzi and Ugo Pastorino, respectively. No other potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

We thank Pasquale Simonelli for technical assistance with the imaging experiments.

REFERENCES

- Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med*. 2008;359:1367–1380.
- Politi K, Herbst RS. Lung cancer in the era of precision medicine. *Clin Cancer Res*. 2015;21:2213–2220.
- Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. *Nat Rev Clin Oncol*. 2015;12:511–526.
- Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2013;368:2385–2394.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*. 2005;353:123–132.
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet*. 2005;366:1527–1537.
- Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. *Clin Cancer Res*. 2014;20:2249–2256.
- Zhao Y, Adjei AA. New strategies to develop new medications for lung cancer and metastasis. *Cancer Metastasis Rev*. 2015;34:265–275.
- Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ*. 2008;15:504–514.
- Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci USA*. 2009;106:16281–16286.
- Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. *Nat Rev Clin Oncol*. 2011;8:97–106.
- Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli M. Microenvironment-modulated metastatic CD133+/CXCR4+/EpCAM- lung cancer-initiating cells sustain tumor dissemination and correlate with poor prognosis. *Cancer Res*. 2015;75:3636–3649.
- Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. *Nat Rev Clin Oncol*. 2012;9:338–350.
- Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. *Cancer Res*. 2009;69:3364–3373.
- Hao C, Wang L, Peng S, et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. *Cancer Lett*. 2015;357:179–185.
- Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatient") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov*. 2011;1:508–523.
- Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. *Eur J Cancer*. 2011;47:1231–1243.
- Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol Cancer Ther*. 2011;10:1311–1316.
- Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. *Clin Cancer Res*. 2010;16:1442–1451.
- Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. *Clin Cancer Res*. 2008;14:6456–6468.
- Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. *J Biomed Biotechnol*. 2012;2012:568567–568577.
- Moro M, Bertolini G, Pastorino U, Roz L, Sozzi G. Combination treatment with all-trans retinoic acid prevents cisplatin-induced enrichment of CD133+ tumor-initiating cells and reveals heterogeneity of cancer stem cell compartment in lung cancer. *J Thorac Oncol*. 2015;10:1027–1036.
- Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. *Cancer Cell*. 2012;21:297–308.
- Behzadi A, Ung Y, Lowe V, Deschamps C. The role of positron emission tomography in the management of non-small cell lung cancer. *Can J Surg*. 2009;52:235–242.
- van Gool MH, Aukema TS, Hartemink KJ, Valdes Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. *World J Radiol*. 2014;6:392–398.
- Curtarello M, Zulato E, Nardo G, et al. VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells. *Cancer Res*. 2015;75:120–133.
- Pastorino U, Landoni C, Marchiano A, et al. Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. *J Thorac Oncol*. 2009;4:1352–1356.
- Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer*. 2011;11:85–95.
- Kawada K, Nakamoto Y, Kawada M, et al. Relationship between ^{18}F -fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. *Clin Cancer Res*. 2012;18:1696–1703.
- Mehra E, Forsell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. *Cancer Res*. 2007;67:3970–3975.
- Nishiyama Y, Yamamoto Y, Kanenishi K, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. *Eur J Nucl Med Mol Imaging*. 2008;35:287–295.
- Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. *Lung Cancer*. 2013;79:242–247.
- Shackelford DB, Vasquez DS, Corbeil J, et al. mTOR and HIF-1 α -mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. *Proc Natl Acad Sci USA*. 2009;106:11137–11142.
- Nardo G, Favaro E, Curtarello M, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. *Cancer Res*. 2011;71:4214–4225.
- Xia T, Jiang H, Li C, Tian M, Zhang H. Molecular imaging in tracking tumor stem-like cells. *J Biomed Biotech*. 2012;2012:420364.
- Gaeddicke S, Braun F, Prasad S, et al. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. *Proc Natl Acad Sci USA*. 2014;111:E692–E701.
- Yoshii Y, Furukawa T, Kiyono Y, et al. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. *Nucl Med Biol*. 2010;37:395–404.
- Oh M, Tanaka T, Kobayashi M, et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. *Nucl Med Biol*. 2009;36:419–426.



The Journal of
NUCLEAR MEDICINE

Metabolic Evaluation of Non–Small Cell Lung Cancer Patient–Derived Xenograft Models Using ^{18}F -FDG PET: A Potential Tool for Early Therapy Response

Silvia Valtorta, Massimo Moro, Giovanna Prinszano, Giulia Bertolini, Monica Tortoreto, Isabella Raccagni, Ugo Pastorino, Luca Roz, Gabriella Sozzi and Rosa Maria Moresco

J Nucl Med. 2017;58:42-47.

Published online: October 20, 2016.

Doi: 10.2967/jnumed.116.176404

This article and updated information are available at:

<http://jnm.snmjournals.org/content/58/1/42>

Information about reproducing figures, tables, or other portions of this article can be found online at:

<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:

<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2017 SNMMI; all rights reserved.